These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 37892033)

  • 1. Hepatocellular Carcinoma and Hepatitis: Advanced Diagnosis and Management with a Focus on the Prevention of Hepatitis B-Related Hepatocellular Carcinoma.
    Kim SR; Kim SK
    Diagnostics (Basel); 2023 Oct; 13(20):. PubMed ID: 37892033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B Virus Treatment and Hepatocellular Carcinoma: Controversies and Approaches to Consensus.
    Kim SK; Fujii T; Kim SR; Nakai A; Lim YS; Hagiwara S; Kudo M
    Liver Cancer; 2022 Dec; 11(6):497-510. PubMed ID: 36589728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements.
    Arora A; Singh SP; Kumar A; Saraswat VA; Aggarwal R; Bangar M; Bhaumik P; Devarbhavi H; Dhiman RK; Dixit VK; Goel A; Goswami B; Kapoor D; Madan K; Narayan J; Nijhawan S; Pandey G; Rai RR; Sahu MK; Saraf N; Shalimar ; Shenoy T; Thomas V; Wadhawan M;
    J Clin Exp Hepatol; 2018 Mar; 8(1):58-80. PubMed ID: 29743798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed.
    Lai CL; Wong DK; Wong GT; Seto WK; Fung J; Yuen MF
    JHEP Rep; 2020 Jun; 2(3):100112. PubMed ID: 32462119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?
    Yip TC; Lai JC; Wong GL
    J Gastroenterol; 2020 Nov; 55(11):1023-1036. PubMed ID: 32974760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma.
    Wu JW; Kao JH; Tseng TC
    Clin Mol Hepatol; 2021 Oct; 27(4):524-534. PubMed ID: 33618507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
    Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
    J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir is Superior to Entecavir in Patients with Treatment-naïve Hepatitis B e-Antigen-Positive Chronic Hepatitis B.
    Behera MK; Pati GK; Narayan J; Mishra D; Meher LK; Singh A; Uthansingh K; Sahu MK
    J Clin Exp Hepatol; 2021; 11(1):37-44. PubMed ID: 33679047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues.
    Rapti I; Hadziyannis S
    World J Hepatol; 2015 May; 7(8):1064-73. PubMed ID: 26052395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients.
    Mak LY; Wong DK; Cheung KS; Seto WK; Fung J; Yuen MF
    BMC Gastroenterol; 2021 Mar; 21(1):123. PubMed ID: 33731023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids.
    Arora A; Anand AC; Kumar A; Singh SP; Aggarwal R; Dhiman RK; Aggarwal S; Alam S; Bhaumik P; Dixit VK; Goel A; Goswami B; Kumar A; Kumar M; Madan K; Murugan N; Nagral A; Puri AS; Rao PN; Saraf N; Saraswat VA; Sehgal S; Sharma P; Shenoy KT; Wadhawan M;
    J Clin Exp Hepatol; 2018 Dec; 8(4):403-431. PubMed ID: 30568345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics.
    Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
    J Hepatol; 2016 Jul; 65(1):48-56. PubMed ID: 27034253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients.
    Kaneko S; Kurosaki M; Inada K; Kirino S; Hayakawa Y; Yamashita K; Osawa L; Sekiguchi S; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Itakura J; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2943-2951. PubMed ID: 34057248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
    Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells.
    Aggarwal A; Odorizzi PM; Brodbeck J; van Buuren N; Moon C; Chang S; Adona M; Suthram S; Suri V; Trowe T; Turner S; Marcellin P; Buti M; Gaggar A; Fletcher SP; Diehl L; Feierbach B; Balsitis S
    JHEP Rep; 2023 Apr; 5(4):100664. PubMed ID: 36908748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma.
    Mak LY; Ko KL; To WP; Wong DK; Seto WK; Fung J; Yuen MF
    Gut Liver; 2020 Sep; 14(5):665-668. PubMed ID: 32457279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma.
    Honda M; Shirasaki T; Terashima T; Kawaguchi K; Nakamura M; Oishi N; Wang X; Shimakami T; Okada H; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
    J Infect Dis; 2016 Apr; 213(7):1096-106. PubMed ID: 26621908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Profile and Efficacy of Antivirals in Hepatitis B Virus Reactivation, in Patients With Cancer Receiving Chemotherapy.
    Wani MA; Sodhi JS; Yatoo GN; Shah A; Geelani S; Zargar SA; Gulzar GM; Khan M; Aziz SA
    J Clin Exp Hepatol; 2020; 10(6):590-598. PubMed ID: 33311896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients.
    Wang L; Cao X; Wang Z; Gao Y; Deng J; Liu X; Zhuang H
    J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
    Uchida Y; Nakao M; Tsuji S; Uemura H; Kouyama JI; Naiki K; Motoya D; Sugawara K; Nakayama N; Imai Y; Tomiya T; Mochida S
    J Med Virol; 2020 Mar; 92(3):329-338. PubMed ID: 31777965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.